Published in J Pharmacol Exp Ther on January 01, 1998
In normal rat, intraventricularly administered insulin-like growth factor-1 is rapidly cleared from CSF with limited distribution into brain. Cerebrospinal Fluid Res (2005) 0.95
Treatment of HER2-positive breast carcinomatous meningitis with intrathecal administration of alpha-particle-emitting (211)At-labeled trastuzumab. Nucl Med Biol (2009) 0.91
Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br J Pharmacol (2004) 0.90
Release of plasmid DNA-encoding IL-10 from PLGA microparticles facilitates long-term reversal of neuropathic pain following a single intrathecal administration. Pharm Res (2010) 0.89
PEGylation of brain-derived neurotrophic factor for preserved biological activity and enhanced spinal cord distribution. J Biomed Mater Res A (2009) 0.85
Polysialic acid as an antigen for monoclonal antibody HIgM12 to treat multiple sclerosis and other neurodegenerative disorders. J Neurochem (2015) 0.81
A human anti-polysialic acid antibody as a potential treatment to improve function in multiple sclerosis patients. J Nat Sci (2015) 0.76
Pharmacokinetics of an intracerebroventricularly administered antibody in rats. MAbs (2017) 0.75
Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med (1975) 6.36
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet (2001) 5.80
Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03
Transplantation of multiple abdominal viscera. JAMA (1989) 3.59
Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54
Clinical pharmacokinetics of cyclosporin. Clin Pharmacokinet (1986) 3.53
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Circulating concentrations of nocturnal leptin, growth hormone, and insulin-like growth factor-I increase before the onset of puberty in agonadal male monkeys: potential signals for the initiation of puberty. J Clin Endocrinol Metab (2000) 3.38
Studies on the mechanism of phagocytosis. II. The interaction of macrophages with anti-immunoglobulin IgG-coated bone marrow-derived lymphocytes. J Exp Med (1976) 3.30
Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29
The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation (1991) 3.14
Induction of RNA-stabilized DNA conformers by transcription of an immunoglobulin switch region. Nature (1990) 2.94
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma. J Clin Oncol (1987) 2.81
Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. Nat Genet (1993) 2.72
Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations. Transplant Proc (1990) 2.60
Desmoplastic small round-cell tumor: prolonged progression-free survival with aggressive multimodality therapy. J Clin Oncol (1996) 2.59
Pregnancy after liver transplantation under tacrolimus. Transplantation (1997) 2.50
Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Res (2001) 2.48
Cyclosporine kinetics in renal transplantation. Clin Pharmacol Ther (1985) 2.38
The hepatotropic influence of cyclosporine. Surgery (1990) 2.27
Effect of bile on cyclosporin absorption in liver transplant patients. Br J Clin Pharmacol (1988) 2.21
Chimeric human immunodeficiency virus type 1/type 2 reverse transcriptases display reversed sensitivity to nonnucleoside analog inhibitors. Proc Natl Acad Sci U S A (1991) 2.00
Biliary Excretion of Cyclosporine in Liver Transplant Patients. Transplant Proc (1985) 1.98
Nuclear factor kappa B: important transcription factor and therapeutic target. J Clin Pharmacol (1998) 1.83
Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res (1985) 1.78
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2. Cancer Res (1990) 1.69
Tacrolimus: a new immunosuppressive agent. Am J Health Syst Pharm (1995) 1.69
Disrupted bile acid homeostasis reveals an unexpected interaction among nuclear hormone receptors, transporters, and cytochrome P450. J Biol Chem (2001) 1.67
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol (2001) 1.64
Pharmacokinetics and monitoring of cyclosporine following orthotopic liver transplantation. Semin Liver Dis (1985) 1.61
Twenty years of endodontic success and failure. J Endod (1983) 1.56
Small molecule nerve growth factor analogs image receptors in vivo. Nat Biotechnol (1996) 1.56
Cyclosporine Monitoring and Pharmacokinetics in Pediatrie Liver Transplant Patients. Transplant Proc (1985) 1.55
Transcription induces the formation of a stable RNA.DNA hybrid in the immunoglobulin alpha switch region. J Biol Chem (1994) 1.49
Non-B right-handed DNA conformations of homopurine.homopyrimidine sequences in the murine immunoglobulin C alpha switch region. J Biol Chem (1988) 1.49
Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A (1998) 1.48
Pharmacokinetics of orally administered ritodrine. Am J Obstet Gynecol (1989) 1.45
Effects of hexose starvation and the role of sialic acid in influenza virus release. Virology (1983) 1.41
Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-kettering Cancer Center Experience and A Literature Review. Cancer (2001) 1.41
Augmentation of macrophage complement receptor function in vitro. II. Characterization of the effects of a unique lymphokine upon the phagocytic capabilities of macrophages. J Immunol (1980) 1.40
Cyclophosphamide versus ifosfamide in paediatric oncology. Lancet (1990) 1.39
Ciprofloxacin does not block the antiproliferative effect of tacrolimus. Transplantation (1997) 1.39
Treated incidence data. J Am Acad Child Adolesc Psychiatry (1989) 1.38
An assessment of monocyte procoagulant activity in patients with solid tumors. J Surg Res (1987) 1.37
Major histocompatibility proteins, anti-Hu antibodies, and paraneoplastic encephalomyelitis in neuroblastoma and small cell lung cancer. Cancer (1995) 1.36
Biopharmaceutical aspects of FK-506. Transplant Proc (1987) 1.34
Implications of EPHB6, EFNB2, and EFNB3 expressions in human neuroblastoma. Proc Natl Acad Sci U S A (2000) 1.33
Assay of FK 506 in plasma. Transplant Proc (1990) 1.32
Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody. Clin Cancer Res (2001) 1.31
Complete tumor ablation with iodine 131-radiolabeled disialoganglioside GD2-specific monoclonal antibody against human neuroblastoma xenografted in nude mice. J Natl Cancer Inst (1986) 1.31
Sensitivity of activated human lymphocytes to cyclosporine and its metabolites. Hum Immunol (1988) 1.31
The use of human hepatocyte cultures to study the induction of cytochrome P-450. Drug Metab Dispos (1999) 1.30
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes. J Exp Med (1998) 1.30
Detection of leukemia-associated MLL-GAS7 translocation early during chemotherapy with DNA topoisomerase II inhibitors. Proc Natl Acad Sci U S A (2000) 1.29
Effect of cytochalasin B on the maturation of enveloped viruses. J Exp Med (1979) 1.28
Excretion of cyclosporine and its metabolites in human bile. Transplant Proc (1986) 1.27
Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J Clin Oncol (1994) 1.26
GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood (1989) 1.25
Enterovirus meningitis in adults. Clin Infect Dis (1998) 1.25
Role of bile and bile salts on cyclosporine absorption in dogs. Transplant Proc (1987) 1.24
Pharmacokinetics of FK506 in liver transplant recipients after continuous intravenous infusion. J Clin Pharmacol (1993) 1.23
Assessment of the impact of renal impairment on systemic exposure of new molecular entities: evaluation of recent new drug applications. Clin Pharmacol Ther (2008) 1.22
Comparison of UW with other solutions for liver preservation in dogs. Clin Transplant (1989) 1.20
Practical aspects of FK 506 analysis (Pittsburgh experience). Transplant Proc (1991) 1.19
Cerebral infarcts with arterial occlusion in neonates. Ann Neurol (1979) 1.18
Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res (2001) 1.18
Phylogenetic analysis of serotype A foot-and-mouth disease virus isolated in India between 1977 and 2000. Arch Virol (2002) 1.18
Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol (1996) 1.18
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol (2001) 1.16
Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases. Cancer Res (1998) 1.16
Diversity in the germline antibody repertoire. Molecular evolution of the T15 VN gene family. J Exp Med (1985) 1.15
The pattern and tempo of the pubertal reaugmentation of open-loop pulsatile gonadotropin-releasing hormone release assessed indirectly in the male rhesus monkey (Macaca mulatta). Endocrinology (1998) 1.14
Clinical pharmacokinetics in organ transplant patients. Clin Pharmacokinet (1989) 1.14
Synovial sarcoma mimicking desmoplastic small round-cell tumor: critical role for molecular diagnosis. Med Pediatr Oncol (1999) 1.14
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas. Cancer (1992) 1.12
Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clin Cancer Res (2001) 1.11
Immunosuppressive properties of thalidomide. Inhibition of in vitro lymphocyte proliferation alone and in combination with cyclosporine or FK506. Transplantation (1991) 1.10
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. J Clin Oncol (2001) 1.10
Eradication of neuroblastoma cells in vitro by monoclonal antibody and human complement: method for purging autologous bone marrow. Cancer Res (1985) 1.10
Cost effectiveness analysis of intravenous ketorolac and morphine for treating pain after limb injury: double blind randomised controlled trial. BMJ (2000) 1.09
Effect of erythromycin on cyclosporine levels. N Engl J Med (1985) 1.09
Different pathways of differentiation of pre-B cell lines are induced by dendritic cells and T cells from different lymphoid tissues. Cell (1986) 1.09
Bioassay of plasma specimens from liver transplant patients on FK 506 immunosuppression. Transplant Proc (1990) 1.08
Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res (1987) 1.08
IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther (2007) 1.07
Cyclosporine absorption following orthotopic liver transplantation. J Clin Pharmacol (1987) 1.07
Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin Pharmacol Ther (2012) 1.06
Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor kappa B. Transplantation (1999) 1.05
Antipyrine kinetics in liver disease and liver transplantation. Clin Pharmacol Ther (1986) 1.03